Clinical trial • Phase III • Other
CEFTRIAXONE SODIUM for Threatened late miscarriage | Threatened abortion antepartum
Phase III trial of CEFTRIAXONE SODIUM for Threatened late miscarriage | Threatened abortion antepartum. Randomised, open-label. 350 participants.
Overview
- Trial Therapeutic Area
- Other
- Trial Disease
- Threatened late miscarriage | Threatened abortion antepartum
- Trial Stage
- Phase III
- Drug Modality
- Small molecule
Key dates
- Initial CTIS Submission Date
- 13-06-2024
- First CTIS Authorization Date
- 19-09-2024
Trial design
Randomised, open-label Phase III trial in France.
- Randomised
- Yes
- Open Label
- Yes
- Target Sample Size
- 350
Eligibility
Recruits 350 Vulnerable population selected (isVulnerablePopulationSelected = true). Trial enrols pregnant women; inclusion requires maternal age >18 years and adequate understanding of French. Protected persons under guardianship/curatorship/legal protection are explicitly excluded. No explicit assent process described; consent is implied to be provided by the adult participant (maternal consent)..
- Pregnancy Exclusion
- Multiple pregnancies
- Vulnerable Population
- Vulnerable population selected (isVulnerablePopulationSelected = true). Trial enrols pregnant women; inclusion requires maternal age >18 years and adequate understanding of French. Protected persons under guardianship/curatorship/legal protection are explicitly excluded. No explicit assent process described; consent is implied to be provided by the adult participant (maternal consent).
Inclusion criteria
- {"criterion_text":"- Threat of late miscarriage with intact membranes between 18 0/7 and 23 6/7 weeks of gestation, defined by transvaginal ultrasound as a cervix ≤10 mm, and/or protrusion of the amniotic sac observed with a speculum.\n- Singleton pregnancy\n- Living fetus at the time of inclusion\n- Maternal age >18 years\n- Absence of regular and painful uterine contractions\n- Adequate understanding of the French language\n- Affiliated with social security"}
Exclusion criteria
- {"criterion_text":"- Preterm labor defined by regular and painful uterine contractions, and a short cervix\n- Patient under state medical aid (AME) if not exempted from the affiliation requirement\n- Protected person (patient under guardianship/curatorship/legal protection)\n- Multiple pregnancies\n- Premature rupture of membranes\n- Acute chorioamnionitis\n- Contraindication to the antibiotics in the protocol\n- Chromosomal anomaly, congenital malformation\n- Patients who have received antibiotics before inclusion or who require antibiotics for another indication (chorioamnionitis, pyelonephritis, etc.)\n- Participation in another interventional research study or being in the exclusion period following a previous study involving human subjects, if applicable"}
Endpoints
Primary endpoints
- {"endpoint_text":"- Composite criterion combining late miscarriage, perinatal mortality, and/or severe neonatal morbidity occurring before hospital discharge, including: 1-Late miscarriage","definition_or_measurement_approach":"Composite combining late miscarriage, perinatal mortality and severe neonatal morbidity occurring before hospital discharge (as stated)."}
- {"endpoint_text":"- Perinatal mortality","definition_or_measurement_approach":""}
- {"endpoint_text":"- Bronchopulmonary dysplasia","definition_or_measurement_approach":""}
- {"endpoint_text":"- Sepsis proven by blood culture","definition_or_measurement_approach":"Diagnosis proven by positive blood culture."}
- {"endpoint_text":"- Intraventricular hemorrhage ≥ Grade 3","definition_or_measurement_approach":""}
- {"endpoint_text":"- Periventricular leukomalacia ≥ Grade 2","definition_or_measurement_approach":""}
- {"endpoint_text":"- Necrotizing enterocolitis at stage ≥ 2 according to Bell's classification","definition_or_measurement_approach":"Staging according to Bell's classification (stage ≥2)."}
Secondary endpoints
- {"endpoint_text":"- Each item of the composite criterion: 1-Neonatal mortality and late miscarriage","definition_or_measurement_approach":""}
- {"endpoint_text":"- Bronchopulmonary dysplasia according to international recommendations (described by Jobe and Bancalari), diagnosed at discharge or at a corrected age of 36 6/7 weeks of gestation.","definition_or_measurement_approach":"Diagnosis per Jobe and Bancalari criteria at discharge or corrected age 36 6/7 weeks."}
- {"endpoint_text":"- Sepsis proven by culture, diagnosed by a combination of clinical signs and a positive blood culture","definition_or_measurement_approach":"Diagnosis requires clinical signs plus positive culture (blood culture)."}
- {"endpoint_text":"- Intraventricular hemorrhage ≥ Grade 3 and/or periventricular leukomalacia, diagnosed by repeated transfontanellar ultrasounds (according to the classification of Vries and Ment)","definition_or_measurement_approach":"Diagnosis by repeated transfontanellar ultrasounds using Vries and Ment classification."}
- {"endpoint_text":"- Necrotizing enterocolitis ≥ Stage 2, using Bell's classification.","definition_or_measurement_approach":"Staging according to Bell's classification (≥ Stage 2)."}
Recruitment
- Planned Sample Size
- 350
- Recruitment Window Months
- 41
- Consent Approach
- No detailed informed consent process is provided in the available source. Inclusion criteria require maternal age >18 years and adequate understanding of the French language, indicating consent is to be provided by the adult participant; no assent procedures or multilingual documents are described. Protected persons under legal protection are excluded.
Geography
- Total Number Of Sites
- 13
- Total Number Of Participants
- 350
France
- Earliest CTIS Part Ii Submission Date
- 06-08-2024
- Latest Decision Or Authorization Date
- 19-09-2024
- Processing Time Days
- 44
- Number Of Sites
- 13
- Number Of Participants
- 350
Sites
- Site Name
- Centre Hospitalier Universitaire De Bordeaux
- Department Name
- Obstetric gynecology
- Contact Person Name
- Loic SENTILHES
- Contact Person Email
- loic.sentilhes@chu-bordeaux.fr
- Site Name
- Assistance Publique Hopitaux De Paris
- Department Name
- Obstetric gynecology
- Contact Person Name
- Dominique LUTON
- Contact Person Email
- dominique.luton@aphp.fr
- Site Name
- Assistance Publique Hopitaux De Paris
- Department Name
- Obstetric gynecology
- Contact Person Name
- Yves VILLE
- Contact Person Email
- yves.ville@aphp.fr
- Site Name
- Les Hopitaux Universitaires De Strasbourg
- Department Name
- Obstetric gynecology
- Contact Person Name
- Virginie COLLIN-BUND
- Contact Person Email
- virginie.bund@chru-strasbourg.fr
- Site Name
- Centre Hospitalier Intercommunal Creteil
- Department Name
- Obstetric gynecology
- Contact Person Name
- Edouard LECARPENTIER
- Contact Person Email
- edouard.lecarpentier@chicreteil.fr
- Site Name
- Centre Hospitalier Universitaire De Lille
- Department Name
- Obstetric gynecology
- Contact Person Name
- Charles GARABEDIAN
- Contact Person Email
- charles.garabedian@chru-lille.fr
- Site Name
- CHRU De Nancy
- Department Name
- Obstetric-gynécolgy
- Contact Person Name
- Olivier MOREL
- Contact Person Email
- o.morel@chru-nancy.fr
- Site Name
- Assistance Publique Hopitaux De Paris
- Department Name
- Obstetric gynecology
- Contact Person Name
- Camille LE RAY
- Contact Person Email
- camille.le-ray@aphp.fr
- Site Name
- Centre Hospitalier Intercommunal De Poissy Saint Germain
- Department Name
- Obstetric gynecology
- Contact Person Name
- thibaud QUIBEL
- Contact Person Email
- thibaud.quibel@ght-yvelinesnord.fr
- Site Name
- Hospices Civils De Lyon
- Department Name
- O
- Contact Person Name
- Cyril HUISSOUD
- Contact Person Email
- cyril.huissoud@chu-lyon.fr
- Site Name
- Centre Hospitalier Universitaire De Nantes
- Department Name
- Obstetric gynecology
- Contact Person Name
- Norbert WINER
- Contact Person Email
- norbert.winer@chu-nantes.fr
- Site Name
- Assistance Publique Hopitaux De Paris
- Department Name
- Obstetric gynecology
- Contact Person Name
- Lina BEJJANI
- Contact Person Email
- lina.bejjani@aphp.fr
- Site Name
- Assistance Publique Hopitaux De Paris
- Department Name
- Obstetric gynecology
- Contact Person Name
- Gilles KAYEM
- Contact Person Email
- gilles.kayem@aphp.fr
Sponsor
Primary sponsor
- Full Name
- Assistance Publique Hopitaux De Paris
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- France
Third parties
- {"country":"","full_name":"Ministry of Health","duties_or_roles":"Monetary support","organisation_type":""}
Investigational products
- Investigational Product Name
- CEFTRIAXONE VIATRIS 1 g, poudre pour solution injectable
- Active Substance
- CEFTRIAXONE SODIUM
- Modality
- Small molecule
- Routes Of Administration
- SOLUTION FOR INJECTION
- Route
- SOLUTION FOR INJECTION
- Authorisation Status
- Authorised
- Starting Dose
- 1 g
- Maximum Dose
- 1 g
- Investigational Product Name
- Clarithromycine EG 500 mg comprimés pelliculés
- Active Substance
- CLARITHROMYCIN
- Modality
- Small molecule
- Routes Of Administration
- ORAL
- Route
- ORAL
- Authorisation Status
- Authorised
- Starting Dose
- 1.5 g
- Maximum Dose
- 1.5 g
- Investigational Product Name
- MÉTRONIDAZOLE ARROW 500 mg, comprimé pelliculé sécable
- Active Substance
- METRONIDAZOLE
- Modality
- Small molecule
- Routes Of Administration
- ORAL
- Route
- ORAL
- Authorisation Status
- Authorised
- Starting Dose
- 1 g
- Maximum Dose
- 1 g
- Combination Treatment
- Yes
Related trials
Other published trials that may interest you.